Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098222 | 0.83 | PSMB5 (0.47) | ADRA2AHTR2CHTR2BTAAR1PSMB5 | |
| SCHEMBL24780948 | 0.83 | HTR2C (0.32) | HTR2CHTR2B | |
| SCHEMBL2593064 | 0.77 | CYP19A1 (0.41) | CYP19A1CA2ADRA2ATERTHTR2C | |
| SCHEMBL31278211 | 0.73 | KDM1A (0.41) | CYP19A1CA2ADRA2ATERTHTR2C | |
| Hydrochloric Acid SCHEMBL30989938 | 0.71 | KDM1A (0.40) | CYP19A1CA2ADRA2ATERTHTR2C | |
| SCHEMBL1979379 | 0.71 | CYP19A1 (0.37) | CYP19A1CA2ADRA2ATERTHTR2C | |
| SCHEMBL8125243 | 0.71 | CA2 (0.58) | CYP19A1CA2ADRA2AL3MBTL1 | |
| SCHEMBL1979378 | 0.71 | CYP19A1 (0.37) | CYP19A1CA2ADRA2ATERTHTR2C | |
| SCHEMBL6900041 | 0.71 | CYP19A1 (0.37) | CYP19A1CA2ADRA2ATERTHTR2C | |
| SCHEMBL13834855 | 0.71 | CYP19A1 (0.37) | CYP19A1CA2ADRA2ATERTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | CYP19A1 3431/4885CA2 2810/4885ADRA2A 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.